An Update on Anticoagulation in Atrial Fibrillation

Heart Lung and Circulation

Volumn 26, Issue 9, 2017, Pages 911-917

  Amerena, John ^a   Ridley, Daryl ^b  

^a DEAKIN UNIVERSITY   (Australia)

^b University Hospital   (Australia)

Author keywords

Anticoagulation; Atrial fibrillation; Novel anticoagulants; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; HEART VALVE BIOPROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; MEDICAL RESEARCH; MITRAL VALVE REPAIR; PATIENT ATTITUDE; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; THROMBOEMBOLISM; TREATMENT RESPONSE; BLOOD CLOTTING; COMPLICATION; FIBRINOLYTIC THERAPY; GLOBAL HEALTH; INCIDENCE; PROCEDURES; RISK FACTOR;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; GLOBAL HEALTH; HUMANS; INCIDENCE; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY;

EID: 85023760315     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2017.05.131     Document Type: Review

References (38)

1. Diouf, I., Magliano, D.J., Carrington, M.J., Stewart, S., Shaw, J.E., Prevalence, incidence, risk factors and treatment of atrial fibrillation in Australia: The Australian Diabetes, Obesity and Lifestyle (AusDiab) longitudinal, population cohort study. Int J Cardiol 205:Feb (2016), 127–132.
2. Hankey, G.J., Non-valvular atrial fibrillation and stroke prevention. National Blood Pressure Advisory Committee of the National Heart Foundation. Med J Aust 174:Mar (5) (2001), 234–239 Review.
3. Leyden, J.M., Kleinig, T.J., Newbury, J., Castle, S., Cranefield, J., Anderson, C.S., et al. Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. Stroke 44:May (5) (2013), 1226–1231.
4. Lin, H.J., Wolf, P.A., Kelly-Hayes, M., Beiser, A.S., Kase, C.S., Benjamin, E.J., et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 27:Oct (10) (1996), 1760–1764.
5. January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cigarroa, J.E., Cleveland, J.C. Jr, et al. ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130:Dec (23) (2014), 2071–2104.
6. Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:Oct (38) (2016), 2893–2962.
7. Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W., Radford, M.J., Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:Jun (22) (2001), 2864–2870.
8. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm, A.J., Kirchhof, P., Lip, G.Y., Schotten, U., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:Oct (19) (2010), 2369–2429 Erratum in: Eur Heart J. 2011 May;32(9):1172.
9. Hijazi, Z., Lindbäck, J., Alexander, J.H., Hanna, M., Held, C., Hylek, E.M., et al. ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 37:May (20) (2016), 1582–1590.
10. Kakkar, A.K., Mueller, I., Bassand, J.P., Fitzmaurice, D.A., Goldhaber, S.Z., Goto, S., et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 163:Jan (1) (2012), 13–19 e1.
11. Friberg, L., Rosenqvist, M., Lip, G.Y., Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125:May (19) (2012), 2298–2307.
12. No authors listed, Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343:Mar (8899) (1994), 687–691.
13. Hart, R.G., Pearce, L.A., Aguilar, M.I., Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 147:Oct (8) (2007), 590–592.
14. Connolly, S.J., Eikelboom, J., Joyner, C., Diener, H.C., Hart, R., Golitsyn, S., et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 364:Mar (9) (2011), 806–817.
15. No authors listed, Atrial Fibrillation: The Management of Atrial Fibrillation. National Clinical Guideline Centre (UK). 2014, National Institute for Health and Care Excellence (UK), London Jun.
16. Ezekowitz, M.D., Bridgers, S.L., James, K.E., Carliner, N.H., Colling, C.L., Gornick, C.C., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 327:Nov (20) (1992), 1406–1412 Erratum in: N Engl J Med 1993 Jan 14;328(2):148.
17. Shen, A.Y., Yao, J.F., Brar, S.S., Jorgensen, M.B., Chen, W., Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 50:Jul (4) (2007), 309–315.
18. Lee, B.H., Park, J.S., Park, J.H., Park, J.S., Kwak, J.J., Hwang, E.S., et al. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. J Cardiovasc Electrophysiol 21:May (5) (2010), 501–507.
19. Atarashi, H., Inoue, H., Okumura, K., Yamashita, T., Kumagai, N., Origasa, H., J-RHYTHM Registry Investigators. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J 75:6 (2011), 1328–1333.
20. DoHA (Australian Government Department of Health and Ageing), Point of Care Testing in General Practice: Trial Final Report., 2009, ACT, DoHA, Canberra.
21. Bubner, Tanya K., Laurence, Caroline O., Gialamas, Angela, Yelland, Lisa N., Ryan, Philip, Willson, Kristyn J., et al. Effectiveness of point-of-care testing for therapeutic control of chronic conditions: results from the PoCT in General Practice Trial. Med J Aust 190:11 (2009), 624–626.
22. Ruff, C.T., Giugliano, R.P., Braunwald, E., Hoffman, E.B., Deenadayalu, N., Ezekowitz, M.D., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, 383(9921), 2014, 955.
23. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 361(12), 2009, 1139.
24. Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W., et al. ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 365(10), 2011, 883.
25. Granger, C.B., Alexander, J.H., McMurray, J.J., Lopes, R.D., Hylek, E.M., Hanna, M., et al. ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 365(11), 2011, 981.
26. Stangier, J., Clemens, A., Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost, 15(Sep–Oct (Suppl 1)), 2009 9S–16S.
27. Kreutz, R., Pharmacokinetics and pharmacodynamics of rivaroxaban–an oral, direct factor Xa inhibitor. Curr Clin Pharmacol 9:Feb (1) (2014), 75–83.
28. Frost, C., Nepal, S., Wang, J., Schuster, A., Byon, W., Boyd, R.A., et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 76:Nov (5) (2013), 776–786.
29. Chan, N.C., Bhagirath, V., Dale, B.J., Eikelboom, J.W., Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants. Expert Rev Cardiovasc Ther 13:Nov (11) (2015), 1213–1223.
30. Eikelboom, J.W., Wallentin, L., Connolly, S.J., Ezekowitz, M., Healey, J.S., Oldgren, J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulanttherapy (RE-LY) trial. Circulation 123:May (21) (2011), 2363–2372.
31. Eisen, A., Giugliano, R.P., Ruff, C.T., Nordio, F., Gogia, H.S., Awasty, V.R., et al. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. Am Heart J 172:Feb (2016), 144–151.
32. Kakkos, S.K., Kirkilesis, G.I., Tsolakis, I.A., Editor's Choice – efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg 48:Nov (5) (2014), 565–575.
33. Chai-Adisaksopha, C., Hillis, C., Isayama, T., Lim, W., Iorio, A., Crowther, M., Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 13:Nov (11) (2015), 2012–2020.
34. Xu, Y., Schulman, S., Dowlatshahi, D., Holbrook, A.M., Simpson, C.S., Shepherd, L.E., et al. Bleeding Effected by Direct Oral Anticoagulants (BLED-AC) Study Group. Direct oral anticoagulant- or warfarin-related major bleeding: characteristics, reversal strategies and outcomes from a multi-center observational study. Chest(Feb), 2017 pii: S0012-3692(17)30212-X.
35. Majeed, A., Hwang, H.G., Connolly, S.J., Eikelboom, J.W., Ezekowitz, M.D., Wallentin, L., et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 128:Nov (21) (2013), 2325–2332.
36. Pollack, C.V. Jr, Reilly, P.A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R.A., et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 373:Aug (6) (2015), 511–520.
37. Pollack, C.V. Jr, Bernstein, R., Dubiel, R., Reilly, P., Gruenenfelder, F., Huisman, M.V., et al. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. J Med Econ(Jan), 2017, 1–8.
38. Connolly, S.J., Milling, T.J. Jr., Eikelboom, J.W., Gibson, C.M., Curnutte, J.T., Gold, A., et al. ANNEXA-4 Investigators. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 375:Sep (12) (2016), 1131–1141.